Karoon Energy Ltd (ASX: KAR) shares are getting some relief on Monday after a painful stretch for the ASX energy stock.

The Karoon share price is up 8.33% to $1.365 after the company updated investors on its Bauna operations in Brazil.

The bounce comes after a rough two weeks. Karoon shares have fallen more than 30% since the company lowered its CY26 production guidance earlier this month, which put pressure on investor confidence.

With Karoon’s market capitalisation sitting just under $1 billion, today’s update appears to have given investors something more positive to focus on.

Karoon restarts key Bauna well

According to the release, production has been restored from the SPS-92 well at Bauna after Karoon replaced its electrical submersible pump.

Karoon said SPS-92 is currently producing around 8,600 barrels of oil per day.

This means that Bauna production has now lifted to roughly 20,500 barrels per day before natural decline.

Karoon could get another lift from PRA-2 as well. Management expects that well to add around 1,000 to 2,000 barrels per day once it is brought back online, with umbilical work already underway.

SPS-92 has been causing problems since August last year, when a partial pump failure cut production by around 4,500 barrels per day.

While getting it back online doesn’t fix everything, it does ease some of the pressure on Karoon’s recent production outlook.

Higher production, higher costs

Karoon said the final cost of the SPS-92 intervention came in higher than first expected.

This was due to extra rig time, wellbore debris, and equipment-related downtime during the work.

As a result, the company has reviewed its 2026 investment expenditure guidance.

Bauna capex is now expected to be between US$89 million and US$97 million. This is up from the previous guidance range of US$61 million to US$74 million.

Total 2026 capex guidance has also increased to between US$178 million and US$202 million. Previously, Karoon was expecting US$150 million to US$183 million.

Management said the spending is expected to support the long-term value of Bauna and stronger operating cash flow in the second-half of 2026.

Can the rebound continue?

Karoon also gave investors another reason to take a second look.

The company announced that it plans to begin a further on-market share buyback from 1 July 2026.

This follows the recent completion of the second phase of its US$75 million buyback program, which was announced last year.

Management said the next phase will be carried out at a measured pace, with the company taking into account market conditions, capital requirements, and future growth projects.

The buyback should provide support after the recent sell-off, with Karoon saying its shares remain significantly undervalued at current levels.

The post Why this ASX energy stock is jumping 8% after a brutal sell-off appeared first on The Motley Fool Australia.

More reading

• 6 ASX shares with upgraded ratings from experts this week
• Buy, hold, sell: Karoon Energy, Brambles, REA shares
• Oil prices slump to pre-war levels as supply-risk premium evaporates
• 6 ASX shares upgraded by analysts this week
• Why Karoon Energy, Novonix, Transurban, and Woodside shares are sinking today

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Life360 Inc (ASX: 360) shares are making a strong start to the week.

The ASX technology stock jumped 11% to $26.22 during Monday’s lunch-hour trade, extending an impressive recent rebound.

Life360 shares have now climbed around 35% over the past month. Even so, the stock remains well below its October peak and is still down roughly 16% over the past 12 months. By comparison, the S&P/ASX 200 Index (ASX: XJO) has gained about 3% over the same period.

So, what sparked today’s rally?

No major announcement, just improving sentiment

Interestingly, there has been no market-sensitive announcement from the company today. Instead, the buying appears to reflect growing confidence among investors and analysts that Life360’s underlying business is continuing to strengthen.

Life360 operates one of the world’s largest family safety platforms, offering location sharing, crash detection, emergency assistance, digital safety features, and device protection through a subscription-based model.

Its business continues to expand as more families join the platform and existing users upgrade to paid memberships.

Brokers are becoming more optimistic

Analyst sentiment around Life360 shares has steadily improved in recent months. TradingView data shows that 12 out of 13 analysts covering Life360 shares in the past three months rate it a buy or strong buy.

The average price target is $31.88, representing a potential 22% gain at current levels. The most bullish forecast sees a 53% upside, while the most pessimistic prediction sits around the current share price.

One reason for the improved sentiment is Life360’s continued growth in annualised recurring revenue (ARR), which gives investors greater visibility over future earnings.

Sustainable profitability, focus on AI

The company has also made significant progress towards sustainable profitability, easing concerns that high-growth technology companies must continually sacrifice earnings to expand.

Another positive is management’s growing focus on artificial intelligence, with AI expected to improve customer engagement, personalise features, and create additional monetisation opportunities over time.

Valuation is another factor. Following the heavy sell-off earlier this year, Life360 shares now trade on a price-to-earnings (P/E) ratio of roughly 27 times.

For a technology company still delivering strong subscriber growth, many investors see that multiple as increasingly attractive.

In other words, while the share price weakened sharply during the first half of 2026, the business itself continued moving in the opposite direction.

A rotation back into growth stocks?

There’s another possible explanation behind today’s move. Life360 shares were one of the hardest-hit ASX technology stocks during the first half of 2026 as investors rotated away from growth companies.

Now, that trend may be reversing. Stocks that have been heavily sold often rebound sharply when sentiment improves, particularly if the underlying business continues delivering strong operational results.

Whether today’s rally marks the beginning of a sustained recovery remains to be seen.

The post Life360 shares just jumped 11%. Here’s what’s driving the rally appeared first on The Motley Fool Australia.

More reading

• Why I think Life360 and Zip shares are strong buys
• Why this analyst rates Life360 shares a buy right now
• 5 ASX growth shares I want in my portfolio in FY27
• 3 reasons to buy the dip on Life360 shares today
• Buy, hold, sell: Life360, Woodside, CSL shares

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Clarity Pharmaceuticals Ltd (ASX: CU6) were trading more than 10% higher in early trade on Monday after the company said it was going to present data from studies of its prostate cancer detection compound at an esteemed European medical conference.

But what was perhaps more compelling in the company’s announcement was a first person account from a patient who had used the company’s compound and had benefited greatly from it.

New detection methods being developed

Clarity has developed two radiopharmaceutical compounds called 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA which its studies to date show perform well compared with existing detection methods.

The company said it will present various data relating to the compounds at the European Association of Nuclear Medicine (EANM) Annual Congress 2026, which is being held in October in Vienna.

The biotechnology company said regarding the conference:

EANM 2026 Annual Congress is one of the world’s leading nuclear medicine conferences and the acceptance of these abstracts is testament to the strength of the data generated by Clarity’s products and the promising prospects for SAR-bisPSMA to change the paradigm in the diagnosis and treatment of prostate cancer.

The company said one of its trials which will be presented, “demonstrated improved diagnostic performance of 64Cu-SAR-bisPSMA next-day imaging vs. 68Ga-PSMA-11 across all key parameters assessed, including mean number of lesions per participant, total number of lesions, true positive rate and proportion of participants with a positive scan”.

The company will also present data from three client case studies, and said the use of its compound, “changed planned clinical management in all three patients”.

One of the patients, Steve Hunter, also supplied a testimonial.

Compelling first person account

Mr Hunter said he was diagnosed with prostate cancer in 2016, and while his initial treatment was quite successful, blood tests revealed in 2023 that his cancer had returned.

He said:

With SOC PSMA imaging currently available, no lesions were detectable. I was informed by more than one doctor that what I had was a micro-metastatic version of prostate cancer; that is, I had a large number of cancers too small to be detected.

Mr Hunter, himself a medical professional with a history including oncology research, approached Clarity with a view to trying its technology.

He said:

The results were beyond my expectations. Three tumours were found and I underwent targeted external beam radiation. Since then, I have repeated this process with Clarity and (Dr Alan Taylor’s) support a few times to scan, find and subsequently treat the ensuant small number of tumours that arise, with stereotactic radiation therapy. I am so grateful to Clarity in making these scans available. This approach has proven to be highly successful by allowing me to obtain clear information about my disease and defer requiring ADT therapy and all the associated side effects with this treatment.

Clarity shares were trading 14.1% higher at $2.07.  

The post Why is this ASX biotech charging more than 10% higher? appeared first on The Motley Fool Australia.

More reading

• This beaten-down ASX gold stock is jumping on a $300 million deal
• Forget term deposits! I’d buy these two ASX 300 shares instead
• Buy, hold, sell: Wildcat Resources, NAB, Wisetech shares
• Which ASX ETF will pay an eye-popping $18 per share dividend this season?
• What are ASX 200 futures?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.